8/2/2019 Jaskirat

1/16

INDUSTRY RESEARCHPRESENTATION

ON

AstraZeneca IndiaBy

Dr Jaskirat Kaur Kahai

Research Associate and Consultant @

Lobo Selection Services LLP

8/2/2019 Jaskirat

2/16

AstraZeneca plc.

AstraZeneca plc. is a British multinational

pharmaceutical and biologics company

headquartered in London, United Kingdom.

Created in 1999 through the merger of

Swedish Astra AB and British Zeneca Group

plc, it is the world's seventh-largest

pharmaceutical company measured byrevenues and has operations in over 100

countries.

8/2/2019 Jaskirat

3/16

A Brief of History ofAstraZeneca

India AstraZeneca is represented in India as two legal entities

AstraZeneca Pharma India Limited (a listed sales and marketingorganization with a strong manufacturing base in the country) andAstraZeneca India Pvt. Limited (a wholly owned subsidiary ofAstraZeneca PLC engaged primarily in research).

In 1987 Astra Research Centre India (ARCI) was set up in a buildingleased from IDL Chemicals Ltd. at Malleswaram Bangalore.

In 1997 Government of India permitted Astra AB to form 100%owned company (Astra Biochemicals Pvt. Ltd )

In 1999 Astra Research Centre India was renamed AstraZenecaResearch Foundation India to reflect its affiliation with the new

company resulting from the merger of Astra and Zeneca. In 2001 AstraZeneca Pharma India was born, following global

merger between Astra and Zeneca and becomes the first companyin the world to set up a dedicated research centre to find a cure forTuberculosis in Bangalore

8/2/2019 Jaskirat

4/16

A Brief of History ofAstraZeneca

India. Contd.. In 2008 Global sourcing office set up in India designed to

meet AZ Global standards.

In 2009- AstraZeneca collaborates with Jubliant Organosyson neuroscience research, discovered a drug to cure drug

resistant TB and introduced nine new medicines anddoubled its field force.

In 2010- AstraZeneca India announced investments tomodernize and increase the capacity of its manufacturingfacility, teamed up with the Global Alliance for TB to find a

cure for TB. Also, partnered with Medicines for MalariaVentures to look for a cure for malaria, with TorrentPharmaceuticals to supply branded generics ininternational markets and with Bristol Myers Squibb tolaunch a new drug to fight diabetes for Indian patients.

8/2/2019 Jaskirat

5/16

Management

Name Designation

D E Udwadia Chairman / Chair Person

K S Shah Director

Ian Brimicombe Director

Luigi Felice La Corte Director

Anandh Balasundaram Managing Director

8/2/2019 Jaskirat

6/16

Global launch

Director of Branded

Generics KumarSubramaniam

8/2/2019 Jaskirat

7/16

Managing DirectorAnandh Balasundaram

Lead business partnerAsia Pacific Mohan P.

Chief Financial Officer -Himanshu Agarwal

Director, Quality

Assurance andTechnical Services RV

Director StrategicPlanning Gagan Singh

Director, Supply ChainVR

Director, regulatory

Affairs PremnathShenoy

Vice President

Commercial Excellence

GM

Vice president Humanresources AM

Associate DirectorHuman Resources DM

Vice president Legal,

Chief Complianceofficer NS

Vice President

Marketing and salesGanesh Nair

Director Sales and

Marketing SanjeevPanchal

National Sales Director,

Primary care VijaySalian

Sales Director North

and East Zone RanjeetMishra

Regional Business

Manager Delhi ManojSharma

Area Business Manager Sales representative

Director Marketing,Rajeev Nagi

Associate Director ofMarketing Manish

Agrawal

Vice President Medical

Regulatory and ClinicalResearch Paurus Irani

Vice Presidentoperations UM

8/2/2019 Jaskirat

8/16

Director of Chemistry andMetabolic Sciences

Bheemarao Ugarkar

Associate DirectorChemistry Balachandra

Bandodkar

Team Leader Medicinal

Chemistry

Research ScientistMedicinal Chemistry

Regional Medical AffairsDirector Asia Pacific

Namrata B

Associate medicaldirector

Ashish Gulati , ParamjitSingh

General Manager andGroup Medical head

Medical services

Senior Medical advisor Regional Medical Advisor

Manager Medicalservices

8/2/2019 Jaskirat

9/16

Contact AstraZeneca India at

Head office and south zone - Avishkar Post box No. 2483, Off Bellary Road

Hebbal, Bangalore 560 024. Tel: +91-80- 6774 8000

North Zone Office- AstraZeneca Pharma India Limited, C 146, Okhla

Industrial Area, PHASE I,New Delhi- 110020.Tel +91- 011-26371588 OR

+91 011-26371589

West Zone Office- 401-403 Chintamani Plaza, Mohan Studio Compound,

Andheri - Kurla Road, Chakala, Andheri E, Mumbai - 400 099. Tel +91 022

- 67042596 / 28389320/ 28389302. Fax : 022 67042594.

East Zone Office- FMC Fortuna, 4th flr, A-5 234/3A, AJC Bose Road,

Kolkata 700 020, Ph : +91- 033 2283-7940/7941

8/2/2019 Jaskirat

10/16

AstraZeneca Pharma India Limited (AZPIL) is involved

in both the manufacturing and marketing of medicines.

Key healthcare areas products

Cardiovascular

Betaloc, Seloken XL, Imdur,

Ramace,Plendil,, Zestril, Crestor, Seloram,

Vigocil, Nitract SR; Xparin, Valfect

RespiratoryRhinocort, Mits Linctus, Bricarex &

Bricanyl, Symbicort,Clavatrol, Rhinofex

Maternal HealthcareProstodin, Cerviprime, Primiprost &

Partocin, Zoladex 3.6 mg, Gladis, Valenzia

OncologyArimidex, Nolvadex, Iressa, Casodex &

Faslodex

InfectionMeronem & Vancocin CP, Actamace,

,Enclere, Naropin

Pain Control & Anaesthesia Xylocaine & Sensorcaine, Diprivan

Gastrointestinal Neksium

Diabetes Onglyza

f A t Z

8/2/2019 Jaskirat

11/16

Current Turnover ofAstraZeneca

India(Dec '11)

Quarterly

(Mar '11)

YearlyNet Sales 153.48 594.03

Other Income 1.50 6.28

PBDIT 23.88 226.61

Net Profit 14.94 64.13

8/2/2019 Jaskirat

12/16

Unichem Labs

764.74

Novartis India 742.71

Wyeth 635.27

Claris Life 624.90

AstraZeneca 592.87

Shasun Pharma 567.13

Merck 524.76

Indoco Remedies 485.39

Ajanta Pharma 456.78

Arvind Remedies 362.44

Venus Remedies 356.68

http://www.moneycontrol.com/india/stockpricequote/pharmaceuticals/unichemlaboratories/UL02http://www.moneycontrol.com/india/stockpricequote/pharmaceuticals/clarislifesciences/CL02http://www.moneycontrol.com/india/stockpricequote/pharmaceuticals/novartisindia/NI01http://www.moneycontrol.com/india/stockpricequote/pharmaceuticals/clarislifesciences/CL02http://www.moneycontrol.com/india/stockpricequote/pharmaceuticals/wyeth/W11http://www.moneycontrol.com/india/stockpricequote/pharmaceuticals/clarislifesciences/CL02http://www.moneycontrol.com/india/stockpricequote/pharmaceuticals/clarislifesciences/CL02http://www.moneycontrol.com/india/stockpricequote/pharmaceuticals/astrazenecapharma/AZPhttp://www.moneycontrol.com/india/stockpricequote/pharmaceuticals/shasunpharmaceuticals/SCDhttp://www.moneycontrol.com/india/stockpricequote/pharmaceuticals/merck/M12http://www.moneycontrol.com/india/stockpricequote/pharmaceuticals/clarislifesciences/CL02http://www.moneycontrol.com/india/stockpricequote/pharmaceuticals/indocoremedies/IR05http://www.moneycontrol.com/india/stockpricequote/pharmaceuticals/clarislifesciences/CL02http://www.moneycontrol.com/india/stockpricequote/pharmaceuticals/ajantapharma/AP22http://www.moneycontrol.com/india/stockpricequote/pharmaceuticals/arvindremedies/AR06http://www.moneycontrol.com/india/stockpricequote/pharmaceuticals/clarislifesciences/CL02http://www.moneycontrol.com/india/stockpricequote/pharmaceuticals/arvindremedies/AR06http://www.moneycontrol.com/india/stockpricequote/pharmaceuticals/arvindremedies/AR06http://www.moneycontrol.com/india/stockpricequote/pharmaceuticals/arvindremedies/AR06http://www.moneycontrol.com/india/stockpricequote/pharmaceuticals/clarislifesciences/CL02http://www.moneycontrol.com/india/stockpricequote/pharmaceuticals/arvindremedies/AR06http://www.moneycontrol.com/india/stockpricequote/pharmaceuticals/arvindremedies/AR06http://www.moneycontrol.com/india/stockpricequote/pharmaceuticals/arvindremedies/AR06http://www.moneycontrol.com/india/stockpricequote/pharmaceuticals/ajantapharma/AP22http://www.moneycontrol.com/india/stockpricequote/pharmaceuticals/clarislifesciences/CL02http://www.moneycontrol.com/india/stockpricequote/pharmaceuticals/indocoremedies/IR05http://www.moneycontrol.com/india/stockpricequote/pharmaceuticals/clarislifesciences/CL02http://www.moneycontrol.com/india/stockpricequote/pharmaceuticals/merck/M12http://www.moneycontrol.com/india/stockpricequote/pharmaceuticals/shasunpharmaceuticals/SCDhttp://www.moneycontrol.com/india/stockpricequote/pharmaceuticals/astrazenecapharma/AZPhttp://www.moneycontrol.com/india/stockpricequote/pharmaceuticals/clarislifesciences/CL02http://www.moneycontrol.com/india/stockpricequote/pharmaceuticals/clarislifesciences/CL02http://www.moneycontrol.com/india/stockpricequote/pharmaceuticals/wyeth/W11http://www.moneycontrol.com/india/stockpricequote/pharmaceuticals/clarislifesciences/CL02http://www.moneycontrol.com/india/stockpricequote/pharmaceuticals/novartisindia/NI01http://www.moneycontrol.com/india/stockpricequote/pharmaceuticals/clarislifesciences/CL02http://www.moneycontrol.com/india/stockpricequote/pharmaceuticals/unichemlaboratories/UL02http://www.moneycontrol.com/india/stockpricequote/pharmaceuticals/unichemlaboratories/UL02http://www.moneycontrol.com/india/stockpricequote/pharmaceuticals/unichemlaboratories/UL02

8/2/2019 Jaskirat

13/16

Current Turnover ofAstraZeneca

India ContdBalance Sheet (Mar '11) (In Rs Cr)

Total Share Capital 5.00

Net Worth 179.69

Total Debt 0.00Net Block 27.46

Investments 0.01

Net Current Assets 128.30

Total Assets 179.70

8/2/2019 Jaskirat

14/16

On Jul 29, 2010 , US Food and Drug Administration(FDA) Cardiovascular and Renal Drugs AdvisoryCommittee recommended the FDA approve

AstraZenecas investigational drug ticagrelor for thereduction of thrombotic events in patients with AcuteCoronary Syndromes (ACS).

About BRILINTA/BRILIQUE - Ticagrelor(BRILINTA/BRILIQUE) is an investigational oral

antiplatelet treatment for ACS. Ticagrelor is a direct-acting P2Y12 receptor antagonist in a chemical classcalled cyclo-pentyl-triazolo-pyrimidines (CPTPs).Ticagrelor is the first reversibly-binding oral ADPreceptor antagonist.

8/2/2019 Jaskirat

15/16

AstraZeneca India inNews

Shares in AstraZeneca Pharma India Ltd rose on March 6th2012, following a report in the newspaper, citing two peoplefamiliar with the matter, that its parent AstraZeneca Plc wasplanning to delist the Indian unit and was in talks with topinvestment banks.

13 th March 2012- UK's AstraZeneca has partnered with Indiabased Jubilant Life sciences and Belgium's Janssen Pharma.For Big Pharma companies, facing drying R&D pipelines andcost pressures, such an alliance could enhance R&D output,and leverage innovation outside their labs at lower costs.

On 1 March 2012- AstraZeneca announced that MedImmune,

its biologics arm, has received approval from the US Foodand Drug Administration (FDA) for FluMist Quadrivalent(Influenza Vaccine Live, Intranasal) in the prevention ofinfluenza. This marks the first four-strain influenza vaccineapproved by the FDA.

8/2/2019 Jaskirat

16/16

Name of the Companies with Address and Board-line contact details

Name of the Key Persons and Associations in this industry

Basic organization structure of Major potential clients with names (and preferablyMob nos.) of decision makers in each company

Current Turnover of these companies

Nature of Business (products & services)

Competitors (Classify: either Tier 1, Tier 2, Tier 3, etc, or basis product-wise, orMNC, Domestic, etc.)

Branches in India and overseas

No of Employees senior management, middle management, junior level

Equity base financial strengths, funds raised

What are the investments envisaged,

Proposed growth plans

Business Plans and Strategies

Business pain areas that need attention.

Clients and their industries

Technologies working on

Unique selling proposition of the company

Corporate brochures, press releases, balance sheets and Annual reports

No. of manufacturing facilities (if applicable)